Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an ...

Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer ...

H.C. Wainwright analyst Vernon Bernardino reiterated a Hold rating on Cassava Sciences (SAVA – Research Report) today. The company’s shares ...

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) climbed 7% following the company's announcement of securing an exclusive license to a method of treatment patent f ...

Approximately 50,000 people in the United States and more than one million worldwide live with TSC 3. Cassava Sciences, Inc. (NASDAQ: SAVA), is a clinical-stage biotechnology company focused on ...

Investing.com -- Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) climbed 7% following the company’s announcement of securing an exclusive license to a method of treatment patent for its drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Explore Cassava Sciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SAVA. Benzinga Bulls And Bears: Amazon, Tesla, Rivian, Palantir And How Dogecoin ...